Investors Financial Results

Announcements 2022

Glenmark is the first company to launch in India a Triple FDC of Teneligliptin + Pioglitazone + Metformin for Adults with Type 2 Diabetes & High Insulin Resistance

Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg

Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg

Newspaper Publication of Q2 FY 2022-23 Result

Glenmark's MDA Q2 FY 2022 - 23

Glenmark's Q2 FY 2022-23 Results

Glenmark Pharma reports revenue growth of 7.2% YoY and EBITDA margin of 18.4% for Q2 FY 2022-23

Q2 FY23 Earnings Call Invitation - November 14, 2022

Glenmark Pharmaceuticals receives ANDA approval for Sodium Phenylbutyrate Tablets USP, 500 mg

Glenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US

Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination for Adults with Type 2 Diabetes having Comorbidities

Glenmark becomes the First Pharmaceutical Company to launch Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults

Chairman's Speech at the 44th AGM

Proceedings and Scrutinizer's Report of the 44th AGM

Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada

Schedule of Analyst / Institutional Investor Meeting

Hikma launches RYALTRIS™ seasonal allergic rhinitis nasal spray in the US

44th AGM Notice - Newspaper Advertisement

Glenmark AGM Notice 2022

Newspaper Advertisement - Intimation of 44th AGM

Newspaper notice to shareholders for transfer of shares to IEPF

Newspaper Publication of Q1 FY 2022-23 Result

Glenmark's Q1 FY 2022-23 Results

Glenmark's MDA Q1 FY 2022 - 23

Glenmark Pharma reports Revenue of INR 27,773 Mn and PAT of INR 2,111 Mn for Q1 FY 2022-23

Q1 FY23 Earnings Call Invitation - August 12, 2022

Glenmark Pharmaceuticals receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules,1 mg/20 mcg

Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal

Glenmark Pharmaceuticals launches MINYM® GEL – India’s First Topical Minocycline 4% Gel for the Treatment of Moderate to Severe Acne

Glenmark launches Sitagliptin and its Fixed Dose Combinations, at Affordable Price for Adults with Type 2 Diabetes in India

Glenmark Pharmaceuticals Inc., USA continues to expand its Over-The-Counter (OTC) Portfolio with the acquisition of approved ANDAs from Wockhardt Limited

Glenmark becomes the First Pharmaceutical Company to launch Indacaterol + Mometasone Fixed-Dose Combination Drug for Asthma in India

Newspaper Publication of Q4 FY 2021-22 Result

Glenmark's Q4 FY 2021-22 Results

Glenmark's MDA Q4 FY 2021 - 22

Glenmark Pharma reports revenue growth of 5.6% YoY Q4; 12.4% for the full year FY 2021-22

Glenmark Pharmaceuticals receives sANDA approval for Abiraterone Acetate Tablets USP, 500 mg

Q4 FY22 Earnings Call Invitation - May 30, 2022

Board Meeting Intimation – 27th May, 2022

Result of Postal Ballot by remote e-voting & Scrutinizer's Report

Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%

Glenmark receives the ‘India Pharma Innovation of the Year’ Award from the Government of India

Glenmark becomes the first pharmaceutical company to launch Teneligliptin + Pioglitazone Fixed-Dose Combination Drug for Type 2 Diabetes in India

Newspaper Advertisement - Postal Ballot Notice

Notice of Postal Ballot - Disclosure under Regulation 30 of the SEBI LODR Regulations, 2015

Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin's Lymphoma

Glenmark receives ANDA approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg

Newspaper Publication of Q3 FY 2021-22 Result

Glenmark inks agreement with Astrazeneca to commercialize its product Pulmicort Respules® in Columbia

Glenmark’s Q3 FY 2021-22 Results

Glenmark’s MDA Q3 FY 2021 – 22

Glenmark Pharma reports revenue growth of 13.9% and EBITDA growth of 30.8% YoY for Q3 FY 2021-22

Glenmark launches Nitric Oxide Nasal Spray (FabiSpray®) in India for the Treatment of Adult Patients with COVID-19 in partnership with SaNOtize

Q3 FY22 Earnings Call Invitation - February 14, 2022

Board Meeting Intimation - 11th February, 2022

Glenmark Pharmaceuticals receives ANDA approval for Metronidazole Vaginal Gel, 0.75%

Glenmark Pharmaceuticals receives ANDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg

Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray in Singapore, Hong Kong and Vietnam

Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe

Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and

Financial Results Icon


Be a part of the new world

About Us - Governance


The principles that govern us

Investors Report Icon


Performance in numbers

About Us Thumbnail

About Us

Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future